Leiden, The Netherlands, 25 October 2011 – Prosensa, the Dutch company focusing on RNA modulating therapeutics for rare diseases with unmet medical needs, announced today that it has received an innovation credit of up to €5m from AgentschapNL, a subsidiary of the Dutch Ministry of Economic Affairs, Agriculture and Innovation, to support further development of… Continue reading Prosensa Awarded up to €5m Innovation Credit from Dutch Government for research in Myotonic Dystrophy
Blog posts
Prosensa Advances Three Exon Skipping Candidates for Duchenne Muscular Dystrophy into the Next Development Stage
Prosensa to receive up to £27M in development and milestone payments from GSK Leiden, The Netherlands, 13 September 2011 – Prosensa, the Dutch biopharmaceutical company focusing on rare diseases with an unmet medical need, announced today that they have agreed with GlaxoSmithKline (GSK) to advance three further exon skipping compounds (PRO044, PRO045 and PRO053) into… Continue reading Prosensa Advances Three Exon Skipping Candidates for Duchenne Muscular Dystrophy into the Next Development Stage
Mucosis appoints Thomas Johnston as Chief Business Officer
Dutch biotechnology company Mucosis B.V. today announced the appointment of Thomas Johnston as Chief Business Officer. In this role he will have global responsibility for the licensing and marketing of Mucosis’s technologies, negotiating corporate partnerships and other strategic alliances.
Results of Prosensa’s Extended Phase I/II Exon-skipping Trial in Duchenne Muscular Dystrophy Published in the New England Journal of Medicine
Leiden, March 24, 2011 – Prosensa, the Dutch biopharmaceutical company focusing on RNA modulating therapeutics, announces the publication of results from a phase I/II and 12-week extension study of its lead product, PRO051 (GSK2402968) for the treatment of Duchenne Muscular Dystrophy (DMD) in the New England Journal of Medicine (NEJM)[1].
Mucosis starts clinical study with its lead product, FLUGEM™
Dutch biotechnology company Mucosis B.V. today announced the start of a Phase 1 clinical study with its lead product FluGEM™, a novel improved influenza vaccine for the elderly. It is the first-ever study in man with a vaccine candidate based on Mimopath™, a proprietary platform technology for developing more potent vaccines.
